Medarex says licensing partner files IND, triggers milestone payment

By E. Janene Geiss

Philadelphia, Jan. 19 - Medarex, Inc. announced Thursday the filing of an Investigational New Drug Application in the Netherlands by its licensing partner, NovImmune SA, for NI-0401, a fully human antibody that targets the CD3 antigen for the treatment of autoimmune disease.

The antibody product was developed using Medarex's UltiMAb technology, according to a company news release.

Medarex said it expects to receive an undisclosed milestone payment and may receive future milestone payments and royalties should this product candidate progress through clinical development.

"We are pleased with the progress that our partner, NovImmune, has achieved in filing an IND," Donald L. Drakeman, president and chief executive officer of Medarex, said in the release. "With the advancement of the NovImmune antibody into clinical trials, there are now 29 fully human antibodies generated from Medarex's technology that are in clinical development by Medarex and its partners."

Medarex is a Princeton, N.J., biopharmaceutical company focused on development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.